dr. eradat discusses unmet needs in cll
Published 4 years ago • 186 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
1:13
dr. eradat discusses data with acalabrutinib in cll
-
1:05
dr. eradat on novel therapy vs chemotherapy in cll
-
4:09
dr. jain discusses unmet needs in cll, richter's transformation
-
1:58
dr. eradat on the captivate trial in cll
-
1:03
dr. eradat on rituximab biosimilar in cd20 b-cell nhl and cll
-
1:09
dr. sharman on unmet clinical needs in high-risk relapsed/refractory cll
-
0:46
addressing the unmet needs for the treatment of cll
-
0:57
dr. kahl discusses unmet needs in mcl
-
1:47
future research priorities and unmet needs in patients with cll
-
0:56
dr. chavez discusses ibrutinib plus venetoclax in cll
-
3:33
addressing unmet needs in cll
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:12
dr. mato on immunotherapy options in cll
-
2:15
dr. kay discusses the role of ibrutinib in cll
-
1:54
dr. fakhri on selecting the optimal treatment in cll
-
0:39
dr. jennifer brown discusses rituximab and ibrutinib in cll
-
1:25
dr. abedin discusses differences between acalabrutinib and ibrutinib in cll
-
1:05
dr. davids discusses findings from duo study in cll
-
1:10
dr. seymour discusses rationale for murano study in cll